Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.30 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8725946 | 0.83 | MLNR (0.33) | MLNREHMT2EHMT1 | |
| SCHEMBL8725909 | 0.82 | EHMT2 (0.33) | MLNREHMT2EHMT1HRH3 | |
| SCHEMBL8724068 | 0.82 | KDM4E (0.43) | ALDH1A1HPGDHTT | |
| SCHEMBL8723649 | 0.80 | MCHR1 (0.36) | ALDH1A1HPGDOPRM1HRH3 | |
| SCHEMBL5906394 | 0.80 | MAPK1 (0.38) | MLNRMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL8724051 | 0.78 | AKR1C3 (0.38) | HTTOPRM1OPRK1EHMT2EHMT1 | |
| SCHEMBL8721281 | 0.78 | HTR6 (0.37) | MLNRMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL8721851 | 0.77 | TDP1 (0.38) | MLNRLMNA | |
| SCHEMBL30909135 | 0.77 | HCRTR1 (0.39) | MLNRKMT2ACNR1CNR2OPRK1 | |
| SCHEMBL8721862 | 0.76 | NPC1 (0.33) | MLNRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| EP-0875513-A1 | Substituted heteroaromatic 5-HT 1F agonists | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | MLNR 1073/4885MEN1 458/4885ALDH1A1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.